Postoperative Nesiritide Use following High-Risk Mitral Valve Replacement


  • John W. C. Entwistle, III
  • David E. McLoughlin
  • Kourosh Baghelai



Nesiritide is primarily used in the treatment of acutely decompensated chronic heart failure. It may also be useful in the postoperative management of patients with an exacerbation of heart failure after cardiac surgery. The management of a patient with cardiogenic shock after acute papillary muscle rupture is described. The patient exhibited signs of postoperative heart failure, and nesiritide therapy was instituted to lower filling pressures and achieve diuresis. This drug may be useful when patients with heart failure undergo cardiac surgery and continue to show evidence of heart failure in the postoperative period.


Colucci WS, Elkayam U, Horton DP, et al. 2000. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343:246-53.nHobbs RE, Mills RM, Young JB. 2001. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 10:935-42.nMoazami N, Damiano RJ, Bailey MS, et al. 2003. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 75:1974-6.nSilver MA, Horton DP, Ghali JK, Elkayam U. 2002. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39:798-803.n



How to Cite

Entwistle, III, J. W. C., McLoughlin, D. E., & Baghelai, K. (2005). Postoperative Nesiritide Use following High-Risk Mitral Valve Replacement. The Heart Surgery Forum, 7(3), E189-E190.